Study Of Clinical Effect And Safety Of Ticagrelor To Interventional Treatment For Patients With Acute Coronary Syndrome In The Short And Medium-term

Objective By observing the patients with acute coronary syndrome (ACS) who suffer coronary artery intervention (PCI) apply for Ticagrelor treatment for 12 months,carries on the preliminary research and discussion in ACS interventional therapy for the clinical effect and safety of Ticagrelor.Methods Our hospital diagnosed as acute coronary syndrome patients with interventional treatment, were randomly divided into group Ticagrelor and group Clopidogrel from April 2013 to October 2013 period of 60 patients,30 cases in each group of patients. For Ticagrelor group (23 cases of male, female 7) give aspirin+for Ticagrelor treatment, Clopidogrel group (21 cases in men and 9 women)+Clopidogrel to aspirintreatment. Two groups of patients according to individual differences in application of coronary heart disease (CHD) secondary prevention drugs. Observation duringhospitalization and follow-up of 1 year the incidence of postoperative acute, subacute, and late thrombosis and cardiovascular adverse events (MACE, including cardiac death, nonfatalmyocardial infarction, target lesion reascularization) and bleeding events (including fatalbleeding, severe bleeding, minor bleeding, etc.), to evaluate for clinical effect and safety of Ticagrelor patients with ACS.Results1. Two groups of patients before treatment of gender, age, hypertension, hyperlipidemia, diabetes, smoking, unstable angina (UA) and acute myocardial infarction (AMI) and old myocardial infarction (OMI) and PCI, left ventricular ejection fraction were no obvious difference, there was no statistically significant difference.2. Thetwo groups of patients in the lesion blood vessel number, lesion blood vessel type, lesion degree of stenosis, and there is no statistical difference of average length.3. Ticagrelor group compared with Clopidogrel group, two groups of PCI postoperative 12months total MACE and stent thrombosis in patients with comparison there was no statistically significant difference. No statistical difference of two groups of patients with hemorrhages. Two groups of follow-up were nothing but lethal myocardial infarction occurred.Conclusions Ticagrelor reversible effects on P2Y12 ADP receptors, inhibit adenosine diphosphate (ADP) mediated platelet activation and aggregation,give play to the role of platelet. Compared with clopidogrel, Ticagrelor to interventional therapy with ACS patients is safe and effective for at least 12 months, both in reducing major adverse cardiac events, reduce stent restenosis and stent thrombosis, there was no significant difference in all can obtain satisfactorv clinical effect. and does not increase the risk of bleeding.